Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Avadel Pharmaceuticals

Avadel Pharmaceuticals Joins Rank Of Stocks With 95-Plus Composite Rating

On Thursday, Avadel Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.

Investors Business Daily

Avadel Pharmaceuticals Shows Rising Price Performance With Jump To 91 RS Rating

Avadel Pharmaceuticals Shows Rising Price Performance With Jump To 91 RS Rating

A Relative Strength Rating upgrade for Avadel Pharmaceuticals shows improving technical performance.

Investors Business Daily

Stocks Showing Rising Market Leadership: Avadel Pharmaceuticals Earns 87 RS Rating

Stocks Showing Rising Market Leadership: Avadel Pharmaceuticals Earns 87 RS Rating

Avadel Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 87.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Stocks With Robust Growth Outlooks Insiders Are Buying

Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025.

Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82

Avadel Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 82.

Investors Business Daily

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap of Tuesday's Biotech Catalysts - End Of The Day Summary

Recap of Tuesday's Biotech Catalysts - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Intraday Session

41 Stocks Moving In Friday's Mid-Day Session

41 Stocks Moving In Friday's Mid-Day Session

Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares rose 60.2% to $1.7136. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.

Recap: Avadel Pharmaceuticals Q4 Earnings

Recap: Avadel Pharmaceuticals Q4 Earnings

Avadel Pharmaceuticals (NASDAQ:AVDL) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Earnings Preview: Avadel Pharmaceuticals

Earnings Preview: Avadel Pharmaceuticals

Avadel Pharmaceuticals (NASDAQ:AVDL) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement. Analysts estimate that Avadel Pharmaceuticals will report an earnings per share (EPS) of $-0.41.

Organisations

US Food and Drug Administration

Smithfield Foods

Avadel Pharmaceuticals

CASI Pharmaceuticals

Mirati rapeutics

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play